Stockholm - Free Realtime Quote SEK
CombiGene AB (publ) (COMBI.ST)
As of 11:20 AM GMT+2. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
1,915.1170
5,544.1170
26,699.2820
84,041.5710
--
--
Operating Expense
41,373.1050
44,144.1050
46,161.3660
63,447.7780
29,360.8800
--
Operating Income
-39,457.9880
-38,599.9880
-19,462.0840
20,593.7930
-29,360.8800
--
Net Non Operating Interest Income Expense
2,935.5850
2,934.5850
790.1450
0.0240
-1,392.0770
--
Pretax Income
-36,523.4030
-35,665.4030
-6,156.9310
20,964.9150
-29,551.4300
--
Net Income Common Stockholders
-36,523.4030
-35,665.4030
-6,156.9310
20,964.9150
-29,382.7790
--
Diluted NI Available to Com Stockholders
-36,523.4030
-35,665.4030
-6,156.9310
20,964.9150
-29,382.7790
--
Basic EPS
-1.84
-1.80
-0.31
1.21
-3.31
--
Diluted EPS
-1.84
-1.80
-0.31
1.21
-3.31
--
Basic Average Shares
19,801.1970
19,801.1970
19,801.1970
17,311.4140
8,939.0080
--
Diluted Average Shares
19,801.1970
19,801.1970
19,801.1970
17,311.4140
8,939.0080
--
Total Operating Income as Reported
--
-38,599.9880
-6,947.0750
20,964.8910
-28,159.3530
--
Total Expenses
41,373.1050
44,144.1050
46,161.3660
63,447.7780
29,360.8800
--
Net Income from Continuing & Discontinued Operation
-36,523.4030
-35,665.4030
-6,156.9310
20,964.9150
-29,382.7790
--
Normalized Income
-36,523.4030
-35,665.4030
-6,156.9310
20,964.9150
-29,382.7790
--
Interest Income
--
2,939.3860
791.8270
0.0240
0.0050
--
Interest Expense
--
4.8010
1.6820
--
1,392.0820
--
Net Interest Income
2,935.5850
2,934.5850
790.1450
0.0240
-1,392.0770
--
EBIT
-36,518.6020
-35,660.6020
-6,155.2490
20,964.9150
-28,159.3480
--
EBITDA
-33,806.4340
-33,036.4340
-3,560.4210
23,559.7430
-25,664.5200
--
Reconciled Depreciation
2,712.1680
2,624.1680
2,594.8280
2,594.8280
2,494.8280
--
Net Income from Continuing Operation Net Minority Interest
-36,523.4030
-35,665.4030
-6,156.9310
20,964.9150
-29,382.7790
--
Normalized EBITDA
-33,806.4340
-33,036.4340
-3,560.4210
23,559.7430
-25,664.5200
--
12/31/2019 - 5/25/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
KAN.ST Kancera AB (publ)
1.8880
0.00%
ELIC.ST Elicera Therapeutics AB (publ)
1.4700
-3.92%
SPRINT.ST Sprint Bioscience AB (publ)
1.8000
+1.12%
LPGO.ST Lipigon Pharmaceuticals AB (publ)
0.1854
+0.76%
SCOL.ST Scandion Oncology A/S
0.1320
+1.54%
FLUI.ST Fluicell AB (publ)
0.0758
+2.99%
XBRANE.ST Xbrane Biopharma AB (publ)
0.2170
+20.56%
BINV.ST BioInvent International AB (publ)
43.60
-2.68%
ONCO.ST Oncopeptides AB (publ)
2.0650
-0.96%
EXPRS2.ST ExpreS2ion Biotech Holding AB (publ)
0.9180
+2.46%